Cargando…

The Strategies of Development of New Non-Toxic Inhibitors of Amyloid Formation

In recent years, due to the aging of the population and the development of diagnostic medicine, the number of identified diseases associated with the accumulation of amyloid proteins has increased. Some of these proteins are known to cause a number of degenerative diseases in humans, such as amyloid...

Descripción completa

Detalles Bibliográficos
Autores principales: Galzitskaya, Oxana V., Grishin, Sergei Y., Glyakina, Anna V., Dovidchenko, Nikita V., Konstantinova, Anastasiia V., Kravchenko, Sergey V., Surin, Alexey K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9964835/
https://www.ncbi.nlm.nih.gov/pubmed/36835194
http://dx.doi.org/10.3390/ijms24043781
_version_ 1784896607061278720
author Galzitskaya, Oxana V.
Grishin, Sergei Y.
Glyakina, Anna V.
Dovidchenko, Nikita V.
Konstantinova, Anastasiia V.
Kravchenko, Sergey V.
Surin, Alexey K.
author_facet Galzitskaya, Oxana V.
Grishin, Sergei Y.
Glyakina, Anna V.
Dovidchenko, Nikita V.
Konstantinova, Anastasiia V.
Kravchenko, Sergey V.
Surin, Alexey K.
author_sort Galzitskaya, Oxana V.
collection PubMed
description In recent years, due to the aging of the population and the development of diagnostic medicine, the number of identified diseases associated with the accumulation of amyloid proteins has increased. Some of these proteins are known to cause a number of degenerative diseases in humans, such as amyloid-beta (Aβ) in Alzheimer’s disease (AD), α-synuclein in Parkinson’s disease (PD), and insulin and its analogues in insulin-derived amyloidosis. In this regard, it is important to develop strategies for the search and development of effective inhibitors of amyloid formation. Many studies have been carried out aimed at elucidating the mechanisms of amyloid aggregation of proteins and peptides. This review focuses on three amyloidogenic peptides and proteins—Aβ, α-synuclein, and insulin—for which we will consider amyloid fibril formation mechanisms and analyze existing and prospective strategies for the development of effective and non-toxic inhibitors of amyloid formation. The development of non-toxic inhibitors of amyloid will allow them to be used more effectively for the treatment of diseases associated with amyloid.
format Online
Article
Text
id pubmed-9964835
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99648352023-02-26 The Strategies of Development of New Non-Toxic Inhibitors of Amyloid Formation Galzitskaya, Oxana V. Grishin, Sergei Y. Glyakina, Anna V. Dovidchenko, Nikita V. Konstantinova, Anastasiia V. Kravchenko, Sergey V. Surin, Alexey K. Int J Mol Sci Review In recent years, due to the aging of the population and the development of diagnostic medicine, the number of identified diseases associated with the accumulation of amyloid proteins has increased. Some of these proteins are known to cause a number of degenerative diseases in humans, such as amyloid-beta (Aβ) in Alzheimer’s disease (AD), α-synuclein in Parkinson’s disease (PD), and insulin and its analogues in insulin-derived amyloidosis. In this regard, it is important to develop strategies for the search and development of effective inhibitors of amyloid formation. Many studies have been carried out aimed at elucidating the mechanisms of amyloid aggregation of proteins and peptides. This review focuses on three amyloidogenic peptides and proteins—Aβ, α-synuclein, and insulin—for which we will consider amyloid fibril formation mechanisms and analyze existing and prospective strategies for the development of effective and non-toxic inhibitors of amyloid formation. The development of non-toxic inhibitors of amyloid will allow them to be used more effectively for the treatment of diseases associated with amyloid. MDPI 2023-02-14 /pmc/articles/PMC9964835/ /pubmed/36835194 http://dx.doi.org/10.3390/ijms24043781 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Galzitskaya, Oxana V.
Grishin, Sergei Y.
Glyakina, Anna V.
Dovidchenko, Nikita V.
Konstantinova, Anastasiia V.
Kravchenko, Sergey V.
Surin, Alexey K.
The Strategies of Development of New Non-Toxic Inhibitors of Amyloid Formation
title The Strategies of Development of New Non-Toxic Inhibitors of Amyloid Formation
title_full The Strategies of Development of New Non-Toxic Inhibitors of Amyloid Formation
title_fullStr The Strategies of Development of New Non-Toxic Inhibitors of Amyloid Formation
title_full_unstemmed The Strategies of Development of New Non-Toxic Inhibitors of Amyloid Formation
title_short The Strategies of Development of New Non-Toxic Inhibitors of Amyloid Formation
title_sort strategies of development of new non-toxic inhibitors of amyloid formation
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9964835/
https://www.ncbi.nlm.nih.gov/pubmed/36835194
http://dx.doi.org/10.3390/ijms24043781
work_keys_str_mv AT galzitskayaoxanav thestrategiesofdevelopmentofnewnontoxicinhibitorsofamyloidformation
AT grishinsergeiy thestrategiesofdevelopmentofnewnontoxicinhibitorsofamyloidformation
AT glyakinaannav thestrategiesofdevelopmentofnewnontoxicinhibitorsofamyloidformation
AT dovidchenkonikitav thestrategiesofdevelopmentofnewnontoxicinhibitorsofamyloidformation
AT konstantinovaanastasiiav thestrategiesofdevelopmentofnewnontoxicinhibitorsofamyloidformation
AT kravchenkosergeyv thestrategiesofdevelopmentofnewnontoxicinhibitorsofamyloidformation
AT surinalexeyk thestrategiesofdevelopmentofnewnontoxicinhibitorsofamyloidformation
AT galzitskayaoxanav strategiesofdevelopmentofnewnontoxicinhibitorsofamyloidformation
AT grishinsergeiy strategiesofdevelopmentofnewnontoxicinhibitorsofamyloidformation
AT glyakinaannav strategiesofdevelopmentofnewnontoxicinhibitorsofamyloidformation
AT dovidchenkonikitav strategiesofdevelopmentofnewnontoxicinhibitorsofamyloidformation
AT konstantinovaanastasiiav strategiesofdevelopmentofnewnontoxicinhibitorsofamyloidformation
AT kravchenkosergeyv strategiesofdevelopmentofnewnontoxicinhibitorsofamyloidformation
AT surinalexeyk strategiesofdevelopmentofnewnontoxicinhibitorsofamyloidformation